Biophysical analysis in support of development of protein pharmaceuticals

Biophysics for Therapeutic Protein Development

Volumn , Issue , 2013, Pages 173-204

  Alavattam, Sreedhara ^a   Demeule, Barthelemy ^a   Liu, Jun ^a   Yadav, Sandeep ^a   Cromwell, Mary ^a   Shire, Steven J ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924583836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4316-2_8     Document Type: Chapter

References (77)

1. Agostini F, Vendruscolo M, Tartaglia GG (2012) Sequence-based prediction of protein solubility. J Mol Biol 421(2-3):237-241.
2. Andya JD, Hsu CC, Shire SJ (2003) Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5(2):E10.
3. Alavattam S et al (2012) Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci 101(1):21-30.
4. Berkowitz SA (2006) Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J 8(3):E590-E605.
5. Bertolotti-Ciarlet A et al (2009) Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fc gamma receptors. Mol Immunol 46(8-9):1878-1882.
6. Brahms S, Brahms J (1980) Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. J Mol Biol 138(2):149-178.
7. Burkitt W, Domann P, O'Connor G (2010) Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci 19(4):826-835.
8. Byler DM, Susi H (1986) Examination of the secondary structure of proteins by deconvolved Ftir spectra. Biopolymers 25(3):469-487.
9. Cao S, Jiang Y, Narhi LO (2010) A light-obscuration method specific for quantifying subvisible particles in protein therapeutics. Pharmacopeial Forum 36(3):824-834.
10. Carpenter JF et al (2010) Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99(5):2200-2208.
11. Chatelier RC, Minton AP (1987) Sedimentation equilibrium in macromolecular solutions of arbitrary concentration. I. Self-associating proteins. Biopolymers 26(4):507-524.
12. Chen B et al (1999) Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J Pharm Sci 88(4):477-482.
13. Chennamsetty N et al (2009a) Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391(2):404-413.
14. Chennamsetty N et al (2009b) Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106(29):11937-11942.
15. Connolly BD et al (2012) Weak interactions govern the viscosity of concentrated antibody solutions:high-throughput analysis using the diffusion interaction parameter. Biophys J 103:69-78.
16. Demeule B, Shire SJ, Liu J (2009a) A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 388(2):279-287.
17. Demeule B et al (2009b) New methods allowing the detection of protein aggregates: a case study on trastuzumab. MAbs 1(2):142-150.
18. Dong A, Huang P, Caughey WS (1990) Protein secondary structures in water from secondderivative amide I infrared spectra. Biochemistry 29(13):3303-3308.
19. Eigenbrot C et al (1991) X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants. J Mol Biol 221(1):15-21.
20. Fox JA et al (1996) Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279(2):1000-1008.
21. Fraunhofer W, Winter G (2004) The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm 58(2):369-383.
22. Gabrielson JP, Arthur KK (2011) Measuring low levels of protein aggregation by sedimentation velocity. Methods 54(1):83-91.
23. Gibson TJ et al (2011) Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 Monoclonal antibodies. J Pharm Sci 100(3):1009-1021.
24. Giddings JC (2000) The field-flow fractionation family: underlying principles. In: Schimpf ME, Caldwell KD, Giddings JC (eds) Field-flow fractionation handbook. Wiley, New York.
25. Gonzalez JM, Rivas G, Minton AP (2003) Effect of large refractive index gradients on the performance of absorption optics in the Beckman XL-A/I analytical ultracentrifuge: an experimental study. Anal Biochem 313(1):133-136.
26. He F et al (2010a) Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci 99(6):2598-2608.
27. He F et al (2010b) High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399(1):141-143.
28. He F et al (2011) Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci 100(4):1330-1340.
29. Hollander I, Kunz A, Hamann PR (2008) Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem 19(1):358-361.
30. Houde D et al (2009) Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 81(14):2644-2651.
31. Hvidt A, Linderstrom-Lang K (1954) Exchange of hydrogen atoms in insulin with deuterium atoms in aqueous solutions. Biochim Biophys Acta 14(4):574-575.
32. Jackson M, Mantsch HH (1995) The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit Rev Biochem Mol Biol 30(2):95-120.
33. Ji JA et al (2009) Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci 98(12):4485-4500.
34. Johnson WC Jr (1990) Protein secondary structure and circular dichroism: a practical guide. Proteins 7(3):205-214.
35. Kamerzell TJ et al (2011) Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63(13):1118-1159.
36. Kumru OS et al (2012) Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101(2):3636-3650.
37. Lauer TM et al (2012) Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101(1):102-115.
38. Lehermayr C et al (2011) Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J Pharm Sci 100(7):2551-2562.
39. Li CH et al (2011) Applications of circular dichroism (CD) for structural analysis of proteins:qualification of near- and far-UV CD for protein higher order structural analysis. J Pharm Sci 100(11):4642-4654.
40. Liu J et al (1995) Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34(33):10474-10482.
41. Liu J, Ruppel J, Shire SJ (1997) Interaction of human IgE with soluble forms of IgE high affinity receptors. Pharm Res 14(10):1388-1393.
42. Liu J et al (2005) Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94(9):1928-1940.
43. Liu J, Andya JD, Shire SJ (2006) A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J 8(3):E580-E589.
44. Liu D et al (2008) Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47(18):5088-5100.
45. Liu J et al (2012) Assessing and improving asymmetric flow field-flow fractionation of therapeutic proteins. In: Williams KR, Caldwell KD (eds) Field flow fractionation in biopolymer analysis. Springer, New York.
46. Lu Y et al (2008) The effect of a point mutation on the stability of IgG4 as monitored by analytical ultracentrifugation. J Pharm Sci 97(2):960-969.
47. Manta B et al (2011) Tools to evaluate the conformation of protein products. Biotechnol J 6(6):731-741.
48. Minton AP (1989) Analytical centrifugation with preparative ultracentrifuges. Anal Biochem 176(2):209-216.
49. Minton AP, Lewis MS (1981) Self-association in highly concentrated solutions of myoglobin: a novel analysis of sedimentation equilibrium of highly nonideal solutions. Biophys Chem 14(4):317-324.
50. Patel AR, Kerwin BA, Kanapuram SR (2009) Viscoelastic characterization of high concentration antibody formulations using quartz crystal microbalance with dissipation monitoring. J Pharm Sci 98(9):3108-3116.
51. Philo JS (2006) Is any measurement method optimal for all aggregate sizes and types? AAPS J 8(3):E564-E571.
52. Rambaldi DC, Reschiglian P, Zattoni A (2011) Flow field-flow fractionation: recent trends in protein analysis. Anal Bioanal Chem 399(4):1439-1447.
53. RNCOS (2012) Global-protein-therapeutics-market-forecast-to-2015. http://www.pharmaceuticalmarket- research.info/research/PMAAAWUF-Global-Protein-Therapeutics-Market-Forecast-to-2015.shtml.
54. Robinson NE, Robinson AB (2004) Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. J Pept Res 63(5):437-448.
55. Ross PD, Minton AP (1977) Hard quasispherical model for the viscosity of hemoglobin solutions. Biochem Biophys Res Commun 76(4):971-976.
56. Saluja A, Kalonia DS (2004) Measurement of fluid viscosity at microliter volumes using quartz impedance analysis. AAPS PharmSciTech 5(3):e47.
57. Saluja A, Kalonia DS (2005) Application of ultrasonic shear rheometer to characterize rheological properties of high protein concentration solutions at microliter volume. J Pharm Sci 94(6):1161-1168.
58. Saluja A et al (2007) Ultrasonic storage modulus as a novel parameter for analyzing proteinprotein interactions in high protein concentration solutions: correlation with static and dynamic light scattering measurements. Biophys J 92(1):234-244.
59. Saluja A et al (2010) Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 99(8):2657-2665.
60. Samra HS, He F (2012) Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm 9(4):696-707.
61. Scherer TM et al (2010) Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J Phys Chem B 114:12948.
62. Schuck P (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 78(3):1606-1619.
63. Shire SJ, Holladay LA, Rinderknecht E (1991) Self-association of human and porcine relaxin as assessed by analytical ultracentrifugation and circular dichroism. Biochemistry 30(31):7703-7711.
64. Shire SJ, Shahrokh Z, Liu J (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
65. Stafford WF 3rd (1992) Boundary analysis in sedimentation transport experiments: a procedure for obtaining sedimentation coefficient distributions using the time derivative of the concentration profile. Anal Biochem 203(2):295-301.
66. Stephan JP, Kozak KR, Wong WLT (2011) Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6):677-700.
67. Tartaglia GG et al (2005) Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 14(10):2723-2734.
68. Tartaglia GG et al (2008) Prediction of aggregation-prone regions in structured proteins. J Mol Biol 380(2):425-436.
69. Wakankar AA et al (2010) Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem 21(9):1588-1595.
70. Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129-188.
71. Wang WR et al (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48(6-7):860-866.
72. Wu SJ et al (2010) Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 23(8):643-651.
73. Yadav S, Shire SJ, Kalonia DS (2010) Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 99(12):4812-4829.
74. Yadav S et al (2011) Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res 28(7):1750-1764.
75. Yadav S, Shire SJ, Kalonia DS (2012) Viscosity behavior of high-concentration monoclonal antibody solutions: correlation with interaction parameter and electroviscous effects. J Pharm Sci 101(3):998-1011.
76. Zhang A et al (2012) Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29(1):236-250.
77. Zhao H et al (2010) Formulation development of antibodies using robotic system and highthroughput laboratory (HTL). J Pharm Sci 99(5):2279-2294.